The prothrombin time-derived international normalized ratio: Great for Warfarin, fair for prognosis and bad for liver-bleeding risk

Liver International

Volumn 28, Issue 10, 2008, Pages 1325-1327

  Caldwell, Stephen ^a   Shah, Neeral ^a  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; CREATININE; WARFARIN;

ANTICOAGULATION; BLOOD CLOTTING DISORDER; DECOMPENSATED LIVER CIRRHOSIS; DYSFIBRINOGENEMIA; EDITORIAL; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LIVER FAILURE; LIVER HEMORRHAGE; MODEL FOR END STAGE LIVER DISEASE SCORING SYSTEM; PROGNOSIS; PROTHROMBIN TIME; REPRODUCIBILITY; RISK; SCORING SYSTEM;

BLOOD COAGULATION DISORDERS; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE, ACUTE; PROGNOSIS; PROTHROMBIN TIME; WARFARIN;

EID: 54049109633     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01881.x     Document Type: Editorial

References (26)

1. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
2. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
3. Tripodi A. How to implement the modified international normalized ratio for cirrhosis (INR(liver)) for model for end-stage liver disease calculation. Hepatology 2008; 47: 1423-4.
4. Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-46.
5. Lisman T, van Leeuwen Y, Adelmeijer J, et al. Inter-laboratory variability in assessment of the model of end-stage liver disease (MELD) score. Liver Int 2008; in press.
6. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for end-stage liver disease (MELD) based on selection of clinical laboratory. Am J Transpl 2007; 7: 1624-8.
7. Tripodi A, Caldwell SH, Hoffman M, Trotter JF, Sanyal AJ. Review article: The prothrombin time test as a measure of bleeding risk and prognosis in liver disease. Aliment Pharmacol Ther 2007; 26: 141-8.
8. Freeman RB, Wiesner R, Harper A, et al. The new allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8: 851-8.
9. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
10. Kamath PS, Kim WR. The international normalized ratio of prothrombin time in the MELD score: A reliable measure. Clin Liver Dis (in press).
11. Botta F, Giannini E, Romagnoli P. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: A European study. Gut 2003; 52: 134-9.
12. Arjal R, Trotter JF. The international normalized ratio (INR) of prothrombin time in the MELD score: An unreliable measure. Clin Liver Dis (in press).
13. Bellest L, Eschwege V, Poupon R, Chazouilleres O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46: 528-34.
14. Tripodi A, Chantarangkul V, Mannucci PM. The international normalized ratio to prioritize patients for liver transplantation: Problems and possible solutions. J Thromb Haemost 2008; 6: 243-8.
15. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: An evidence-based review. Transfusion 2005; 45: 1413-25.
16. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388-93.
17. Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: Reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46: 727-33.
18. Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6: 79-86.
19. Northup PG, Sundaram V, Fallon MB, et al. Coagulation in Liver Disease Group, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008; 6: 2-9.
20. Northup PG. Hypercoagulation in liver disease. Clin Liver Dis 2008, in press.
21. Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991; 101: 1382-90.
22. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96: 1581-6.
23. Xavier E, Park SH, May DS, et al. Comparison of conventional tests with thromboelastography in assessing bleeding risk among decompensated cirrhosis patients. Hepatology 2007; 46: 588A.
24. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.
25. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: The role of platelets. Hepatology 2006; 44: 440-5.
26. Shah N, Caldwell S, Berg C. The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: Prophylactic versus rescue? 2008; in press.